C. Bosch

781 total citations
16 papers, 464 citations indexed

About

C. Bosch is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C. Bosch has authored 16 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Surgery and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C. Bosch's work include Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (5 papers) and Colorectal and Anal Carcinomas (4 papers). C. Bosch is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Cancer Treatment and Pharmacology (5 papers) and Colorectal and Anal Carcinomas (4 papers). C. Bosch collaborates with scholars based in Spain, United States and Netherlands. C. Bosch's co-authors include P. Escudero, María José Safont, Jorge Aparicio, Antonieta Salud, Joan Maurel, Carlos Fernández-Martos, Bartomeu Massutí, Clara Montagut, Xabier García‐Albéniz and Bruce D. Minsky and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and British Journal of Cancer.

In The Last Decade

C. Bosch

16 papers receiving 458 citations

Peers

C. Bosch

ONCOL

SURGE

PRM

HEPAT

Yu Nakaji Japan

E. Oevermann Germany

Guillermo Ojea Quintana Argentina

C.J.A. Punt Netherlands

Marco Stella Italy

Carlo Barone Italy

J Lokich United States

Jean Philippe Metges France

Chaoyang Gu China

Masashi Yahagi Japan

Yu Nakaji Japan

C. Bosch

230 ×0.6

ONCOL

213 ×0.9

SURGE

214 ×1.8

PRM

99 ×1.2

23 ×0.6

HEPAT

Citations per year, relative to C. Bosch C. Bosch (= 1×) peers Yu Nakaji

Countries citing papers authored by C. Bosch

Since Specialization

Citations

This map shows the geographic impact of C. Bosch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Bosch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Bosch more than expected).

Fields of papers citing papers by C. Bosch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Bosch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Bosch. The network helps show where C. Bosch may publish in the future.

Co-authorship network of co-authors of C. Bosch

This figure shows the co-authorship network connecting the top 25 collaborators of C. Bosch. A scholar is included among the top collaborators of C. Bosch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Bosch. C. Bosch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Pineda, Estela, Antonieta Salud, Jorge Aparicio, et al.. (2017). Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. Tumor Biology. 39(6). 3726132150–3726132150. 7 indexed citations

Feliú, Jaime, Antonieta Salud, María José Safont, et al.. (2015). Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer. PLoS ONE. 10(1). e0116527–e0116527. 34 indexed citations

Fernández-Martos, Carlos, Xabier García‐Albéniz, Carles Pericay, et al.. (2015). Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Annals of Oncology. 26(8). 1722–1728. 233 indexed citations

Fernández-Martos, Carlos, Carles Pericay, Jorge Aparicio, et al.. (2014). Chemoradiation (CRT) followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant CRT and surgery for locally advanced rectal cancer: Results of the Spanish GCR-3 randomized phase II trial after a median follow-up of 5 years.. Journal of Clinical Oncology. 32(3_suppl). 383–383. 9 indexed citations

Feliú, Jaime, Antonieta Salud, María José Safont, et al.. (2014). First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. British Journal of Cancer. 111(2). 241–248. 22 indexed citations

Feliú, Jaime, María José Safont, Antonieta Salud, et al.. (2010). Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. British Journal of Cancer. 102(10). 1468–1473. 39 indexed citations

Feliú, Jaime, M. J. Safont, Antonieta Salud, et al.. (2009). Phase II study to evaluate the efficacy of capecitabine combined with bevacizumab as first-line treatment in elderly patients with advanced or metastatic colorectal adenocarcinoma. Journal of Clinical Oncology. 27(15_suppl). 4119–4119. 1 indexed citations

Feliú, Jaime, M. J. Safont, Ferrán Losa, et al.. (2008). First-line treatment with bevacizumab plus capecitabine for elderly patients with metastatic colorectal cancer: BECA trial. Journal of Clinical Oncology. 26(15_suppl). 15120–15120. 6 indexed citations

Muñoz-Langa, José, Óscar Juan, C. Molins‐Legua, et al.. (2008). Predictive model of response to epoetin-alfa in anemic patients with solid tumors receiving chemotherapy: Results from a multicenter prospective study. Journal of Clinical Oncology. 26(15_suppl). 20607–20607. 1 indexed citations

10.

Fernández-Martos, Carlos, Ivonne Romero, Jorge Aparicio, et al.. (2006). Preoperative uracil/tegafur and concomitant radiotherapy in locally advanced rectal (LAR) cancer: Updated results with a median follow-up of 5 years and analysis of prognostic factors (PF). Journal of Clinical Oncology. 24(18_suppl). 3573–3573. 1 indexed citations

11.

Muñoz-Langa, José, Óscar Juan, C. Molins‐Legua, et al.. (2005). Once-weekly dosing of epoetin alfa are similar to three-times-weekly dosing to improve hemoglobin levels in chemotherapy patients: Results From multicenter prospective cohort study. Journal of Clinical Oncology. 23(16_suppl). 8161–8161. 1 indexed citations

12.

Hage, Jos A. van der, Lambert J. C. M. Van den Broek, Catherine Legrand, et al.. (2004). Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. British Journal of Cancer. 90(8). 1543–1550. 76 indexed citations

13.

Aparicio, Jorge, I. Maestu, C. Bosch, et al.. (2003). Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Annals of Oncology. 14(7). 1121–1125. 19 indexed citations

14.

Montalar, Joaquín, Ángel Segura, C. Bosch, et al.. (2002). Cefepime Monotherapy as an Empirical Initial Treatment of Patients with Febrile Neutropenia. Medical Oncology. 19(3). 161–166. 9 indexed citations

15.

Aguilera, Cristina, C. Bosch, Josep Maria Castel, et al.. (1997). [Analgesics in the postoperative period of abdominal interventions. The Study Group on Postoperative Analgesia of the Spanish Society of Clinical Pharmacology].. PubMed. 108(4). 136–40. 4 indexed citations

16.

Becker, Michael W., et al.. (1981). [Progressive intrahepatic cholestasis (author's transl)].. PubMed. 129(9). 515–20. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact